Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| GRAIL | 16 | - | -0,23 % | ||
| MODERNA | 6 | 16 | +0,44 % | ||
| BIONTECH | 5 | 13 | +2,19 % | ||
| AMICUS THERAPEUTICS | 4 | 1 | 0,00 % | ||
| BIOGEN | 3 | 54 | -0,18 % | ||
| AMGEN | 3 | 27 | +0,13 % | ||
| MADRIGAL PHARMACEUTICALS | 3 | 7 | -1,57 % | ||
| GUARDANT HEALTH | 3 | 2 | -2,47 % | ||
| CANDEL THERAPEUTICS | 3 | 1 | -14,29 % | ||
| SAVARA | 3 | - | 0,00 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09:50 | Samstag-Meldung zu BIONTECH SE ADR: Jetzt könnte es explodieren! | 3 | Maximilian Berger | ||
| 07:58 | 71% Potenzial! Warum Tempus AI Anleger reizt | 9 | Investing.com Deutsch | ||
| 03:48 | Vanda surges as FDA approves Bysanti for bipolar disorder, schizophrenia | 5 | Seeking Alpha | ||
| 00:06 | FDA approves Vanda's Bysanti for bipolar disorder, schizophrenia | 4 | Investing.com | ||
| Fr | Vanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Announces FDA Approval of BYSANTI (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation | 161 | PR Newswire | WASHINGTON, Feb. 20, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved... ► Artikel lesen | |
| Fr | BioMarin Pharmaceutical Q4 2025 Earnings Preview | 2 | Seeking Alpha | ||
| Fr | Summit Therapeutics Q4 2025 Earnings Preview | 2 | Seeking Alpha | ||
| Fr | Vir Biotechnology Q4 2025 Earnings Preview | 1 | Seeking Alpha | ||
| Fr | Strong Analyst Confidence in C4 Therapeutics (CCCC)'s Cemsidomide Drives 270% Upside Potential | 1 | Insider Monkey | ||
| Fr | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | 8 | GlobeNewswire (USA) | ||
| Fr | The Analyst Verdict: Amgen In The Eyes Of 18 Experts | 3 | Benzinga.com | ||
| Fr | Expert Outlook: Beam Therapeutics Through The Eyes Of 4 Analysts | 1 | Benzinga.com | ||
| Fr | 5 Analysts Assess GRAIL: What You Need To Know | 3 | Benzinga.com | ||
| Fr | FDA to review Savara resubmitted Molbreevi BLA | 1 | Seeking Alpha | ||
| Fr | FDA nimmt Zulassungsantrag von Savara für Medikament gegen seltene Lungenkrankheit an | 2 | Investing.com Deutsch | ||
| Fr | FDA accepts Savara's drug application for rare lung disease | 2 | Investing.com | ||
| Fr | Ultragenyx Pharmaceutical Inc.: Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| Fr | Grail Stock Is Deeply Oversold on Cancer Test Failings. Is There Any Hope Left to Buy the Dip? | 8 | Barchart.com | ||
| Fr | Manuela Buxo To Become Head of Sanofi's (SNY) Specialty Care Global Business Unit | 3 | Insider Monkey | ||
| Fr | Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.